Digestive neuroendocrine tumours (carcinoids) derive from serotonin-producing enterochromaffin cells. Biochemical screening (and follow-up) is performed with measurements of 5-hydroxyindoloacetic acid in urine. Other markers are also useful. Most digestive neuroendocrine tumours are better localised with functional imaging, i.e. nuclear medicine, compared with other modalities. The treatment of choice is surgical; non-resectable tumours are treated with somatostatin analogues (unlabelled and for more advanced disease radiolabelled) or chemotherapy. Most pheochromocytomas/paragangliomas are sporadic, however, and genetically caused tumours are much more common than previously thought. Biochemical proof of disease is best carried out with measurement of plasma metadrenaline. Imaging with computed tomography or magnetic resonance imaging (MRI) should be followed by functional imaging. 
Levels of 5-HIAA also correlate with tumour burden (sensitivity is 70% whereas specificity is 90-100%). 2 Chromogranin A is a marker with a sensitivity of 80-100% for digestive neuroendocrine tumours. 9 Chromogranin A is not specific for these; however, it is also used as a screening test as it is elevated in most cases of metastatic fore-and midgut digestive neuroendocrine tumours. 10, 11 Digestive neuroendocrine tumours in the foregut may also secrete hormones, such as corticotrophin, leading to Cushing's syndrome. 12 Midgut digestive neuroendocrine tumours may synthesise and secrete tachykinins (neurokinin A and substance P), prostaglandins and catecholamines.
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Imaging
Primary digestive neuroendocrine tumours and their metastases, particularly hepatic or in lymph nodes, are evaluated with computed tomography (CT) and magnetic resonance imaging (MRI). The sensitivity of these methods varies from 50-85%. 13 Tumours are multiple in 40% of cases and calcifications are seen in 70% of mesenteric masses. 13 Tumours of 1-2cm are the smallest that are detected. Lesions have a low density on CT scan or low signal in unenhanced MRI views. Lesions are enhanced avidly in the early arterial phase of contrast-enhanced examinations and wash out early. 13 Primary small intestinal tumours are better seen with barium follow-through, conventional or MRI enteroclysis. 14, 15 Functional imaging is better than other modalities in localising primary digestive neuroendocrine tumours.
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Digestive neuroendocrine tumours express somatostatin receptors (STR) 2 and 5. Somatostatin receptor scintigraphy (SRS) has localising sensitivity ranging from 60% (for silent) to 90% (for symptomatic) patients with carcinoid syndrome. 7 Combined SRS/CT evaluation improves imaging compared with standalone SRS. 16 A positive SRS result may also be predictive of response to octreotide therapy. 17 Positron emission tomography (PET) with 68 Ga-DOTATOC (a somatostatin analogue) had 97% sensitivity and 92% specificity in a study of 56 patients with digestive neuroendocrine tumours. 18 These results were better than SRS or CT, which had a sensitivity of 52 and 61% and specificity of 92 and 71%, respectively. In another study of patients with primary or recurrent neuroendocrine tumours, PET with another somatostatin analogue, 68 Ga-DOTATATE, had 82% sensitivity.
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Combined 68 Ga-DOTATOC-PET/CT is better than SRS alone. 20 Scintigraphy with 123 I-metaidobenzylguandine (MIBG) has 60-70% sensitivity in localising digestive neuroendocrine tumours. [21] [22] [23] The combination of SRS and MIBG scintigraphy results may provide even better localising sensitivity.
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Digestive neuroendocrine tumours, similar to other neuroendocrine tumours, take up amine precursors such as dihydroxyphenylalanine (DOPA). PET with 18 F-DOPA has 46-98% sensitivity in detecting such tumours, particularly when it is combined with CT scanning.
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Management
The treatments of choice for digestive neuroendocrine tumours are: 26 endoscopic resection (where possible); limited excision (for tumours <1cm); extensive surgery (for tumors >1cm) and hepatic resection (for liver involvement of <50%). 
Pheochromocytomas/Paragangliomas
Chromaffin cells are post-ganglionic sympathetic neurons that produce catecholamines. They are mainly located in the adrenal medulla.
Nevertheless, accessory adrenal tissue comprising both cortical and medullary elements has been reported to be localised in the celiac plexus area in 16% of autopsy cases.
Tumours arising from extra-adrenal chromaffin cells are termed paragangliomas. They can be found along the paravertebral and para-aortic axes. 53 Sympathetic paraganglia have a neck-to-pelvis distribution and parasympathetic paraganglia are found in the neck and skull base.
Paragangliomas that are localised in the adrenal medulla are called pheochromocytomas (or more uncommonly termed adrenal medullary paragangliomas). 54 The Pheochromocytomas (i.e. adrenal medullary paragangliomas) are rare tumours with an annual incidence of one to four per million population. 55 Furthermore, 0.5% of subjects with hypertension and 4% of those with an incidental adrenal mass have pheochromocytoma. 55 The caveat is that these figures are approximate, since until a few years ago 18-60% of tumours remained undiagnosed. 54 The average lag time from the onset of hypertension to the diagnosis of pheochromocytoma is three years. The symptoms of pheochromocytomas vary. The triad of tachycardia with diaphoresis and cephalalgia is encountered in 40-80% of patients and is highly sensitive and specific for a presumptive diagnosis of pheochromocytoma. 57, 58 Hypertension -newly diagnosed or an exacerbation of known hypertension, most often paroxysmal -is common, occurring in over 90% of patients, but is non-specific. 58 Most paragangliomas are intra-abdominal and adjacent to the adrenals (approximately 85%). Less than 15% are intrathoracic and 1-3% are cervical. 59 Chromaffin-negative neuroendocrine tumours in the head and neck that are related to the parasympathetic nervous system, such as those originating from the carotid bodies or jugular bulbs, are also termed paragangliomas. and their specificity is 89-94 (plasma) and 69-95% (urine). 61 Biochemistry is not only useful for establishing the diagnosis of pheochromocytoma/paraganglioma but can also guide further testing (including genetic testing). In subjects with MEN2 or NF1, there is predominantly elevation in metadrenaline, whereas in subjects with VHL there is predominantly elevation in normetadrenaline. 61 Care must be taken to normalise metadrenaline levels for populations with normal blood pressure, match them for gender and age 74 and avoid interference from medications. 75 Digestive Tract Neuroendocrine Tumours and Pheochromocytomas/Paragangliomas
Dynamic testing is rarely sought. Gucagon testing is now considered to be obsolete. 76 Suppression with clonidine and measurement of plasma-free normetadrenaline is accurate but applies only to normetadrenaline-secreting tumours. 77 Head and neck paragangliomas were previously rarely considered to be hormonally active. A substantial number of them (almost one-third) are, however, biochemically active. This is supported by increased excretion of the dopamine metabolite 3-methoxytyramine. 78 Most abdominal and thoracic SDHB-paragangliomas hypersecrete either normetadrenaline or normetadrenaline and dopamine. Some only hypersecrete dopamine and are almost silent biochemically. 64 
Imaging
CT imaging has 93-100% sensitivity for detecting intra-adrenal pheochromocytomas of approximately 0.5cm in diameter. 79 The sensitivity of CT is slightly lower, at 90%, for localising extra-adrenal disease of approximately 1cm in size. Conventional or MRI angiography may also be very helpful.
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Although positive CT/MRI studies can be diagnostic, their specificity may vary from 50-90%. 55 Thus, negative anatomical imaging studies may not be diagnostic. 83 Furthermore in patients with previous surgery poor quality imaging may lessen utility, particularly if recurrence is suspected. 79 For such cases and for cases of extra-adrenal or malignant/ metastatic disease, the use of functional methods is preferred.
There are two paths for functional imaging of chromaffin tumours:
• Specific methods for these tumours, since chromaffin tumours express the human noradrenaline transporter (hNAT). This permits the use of radiolabelled ligands of molecules that enter the catecholamine synthesis pathway or their analogues and specific vesicular monoamine transporters for storage in intracytoplasmic vesicles.
• Non-specific methods that make use of the high glucose metabolism of tumours or expression of STRs. Dopamine is a catecholamine precursor. PET with 18 F-dopamine is better than 131 I-MIBG for imaging adrenal and/or benign pheochromocytomas or localising metastatic pheochromocytomas. [86] [87] [88] DOPA is converted into dopamine and then transported into pheochromocytomas by hNAT (the large neutral amino acid transporter may also play a role in this). Standalone PET with 18 F-DOPA or combined with CT has been used for localising benign adrenal pheochromocytomas and head and neck paragangliomas with good results. [89] [90] [91] PET with 18 F-labelled deoxyglucose (FDG) is currently widely available and is used for localising various tumours and the staging of neoplastic disease. FDG PET is a convenient and accessible modality for localising pheochromocytomas that are negative with specific functional imaging modalities (particularly metastatic disease).
Pheochromocytomas and paragangliomas express STRs (mostly types 2, 3 and 5), although conflicting results have been presented in the past. [92] [93] [94] [95] [96] [97] Octreotide is an octapeptidic somatostatin analogue that is labelled with 111 In for SRS. Despite intense splachnic/renal abdominal accumulation, it is a useful non-specific tool for localising malignant and/or metastatic pheochromocytomas or paragangliomas with a sensitivity approaching 90%. 98 18 F-dopamine PET/CT is the preferred technique for localising primary pheochromocytomas and paragangliomas and to rule out metastases. 18 F-DOPA PET and 123 I-MIBG scintigraphy make an equally good second choice. For patients with known metastatic paraganglioma, 18 F-dopamine PET is the choice for those with an unknown genotype. 18 F-FDG/ 18 F-dopamine PET should be the preferred option in SDHB mutation carriers. 18 F-DOPA/ 18 F-dopamine PET is preferable in non-SDHB patients.
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Management
The definitive treatment for pheochromocytoma/paraganglioma is surgery.
For hormonally active tumours, a pre-operative blood pressurelowering/normalisation regimen should be followed using selective alpha1 blockers (prazosin, doxazosin and others) or non-selective, non-competitive alpha blockers (phenoxybenzamine). If, despite selectivity tachycardia ensues, beta blockade is given after sufficient alpha blockade has been achieved. 56 Demser is also given to block catecholamine synthesis.
Biochemical evaluation with plasma and/or urine adrenaline should be carried out two to six weeks post-surgery. 53 Annual biochemical work-up for the first five years and once every two years thereafter is
Neuroendocrine Tumours years. 115 In a recent case series of children with pheochromocytoma/ paraganglioma, all were found to harbour a predisposing mutation but were alive after follow-up of five years. 116 In a large cohort of patients with pheochromocytoma, however, mortality from a second neoplasia was four-fold higher compared with that of the general population.
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Recently levels of the adrenomedullin RDC1 receptor were reported to be four times higher in malignant than in benign pheochromocytomas. Cells expressing SNAIL were frequent in metastatic pheochromocytomas compared to being absent in tumours without metastases. Despite these reports, the use of adrenomedullin RDC1 receptor and SNAIL levels as prognostic factors in pheochromocytoma/paraganglioma is not yet envisaged. 71, 118 Pheochromocytoma-paraganglioma syndrome can be diagnosed reliably by immunohistochemistry. 73 There are no criteria to predict survival following malignant pheochromocytoma. Surprisingly, however, 15-year survival rates of almost 50% have been reported with a combination of therapeutic modalities.
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Modalities Currently being Evaluated/Introduced into Practice
Quantification of pheochromocytoma/paraganglioma vesicular monoamine transporter content indicates whether the tumours are MIBG-avid. 95, 96, 120 As PET imaging accessibility increases worldwide, more patients with pheochromocytoma/paraganglioma will be evaluated with PET studies. Ultratrace 131 I-MIBG has very high specific activity and holds promise for future therapeutic applications. 
